In January, Chronosphere raised $115M in venture funding at a $1.6 billion valuation. This news comes on the heels of major milestones for both organizations. We are now providing them with the individualized healthcare they need - on their own terms." "Including FOLX in our benefit offerings underscores our commitment to all of our employees' well being, both physically and mentally. Beyond building internal employee resource groups, we understand that the onus is on us to provide all employees with the benefits and tools they need to lead their best lives - both personally and professionally," said Gabriela Serret-Campos, Global Head of People & Talent at Chronosphere. "We take diversity, equity, and inclusion seriously at Chronosphere. FOLX Health leads with community at the forefront, taking the wants, needs, and feedback of their community into account and in return giving them the resources they deserve. Representation is vital for the LBGTQIA+ community in healthcare settings, where more than half of queer and trans people face discrimination while seeking medical care. "I'm excited to add Chronosphere to our growing list of employers relying on FOLX Health to deliver competent, LGBTQIA+-centric care to their workforce."įOLX Health provides expert, affirming healthcare to the queer and trans community through their skillfully trained clinicians, peer-to-peer support groups, expert-led support groups, library of resources, and enterprise solution that offers a supplementary solution to employers to give their employees the unique healthcare they need. With 50 percent of queer and trans folks not out in the workplace, offering discreet healthcare benefits like ours is more vital than ever," said Liana Douillet Guzmán, CEO of FOLX Health.
Over the past year, in addition to a direct-to-consumer offering, we have started partnering directly with employers to reach their workforce. "Since launching in 2020, FOLX Health's mission has always been to democratize the LGTBQIA+'s community access to equitable healthcare.
0 kommentar(er)
